TrialJournal of the European Academy of Dermatology and Venereology : JEADV2015

Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.

A M Layton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.